Ligand Pharmaceuticals (LGND) Financials: Revenue & Earnings

LGND price $311.79 +0.06 +0.02%

Ticker
LGND
Price
$311.79
Change
+0.06 +0.02%
Market cap ?
$6.22B
P/E ?
30.80
Forward P/E ?
33.36
Dividend yield ?
0.00%
Beta ?
1.01
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
58
Value
24
Quality
81
Growth
69

Stocklytics score rationale: value 24, quality 81, growth 69.

Financials

2016201720182019202020212022202320242025
108973000141102000251453000120282000163562000241544000196245000131314000167133000268087000

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both…

Fair value

LGND fair value $312.43. Price $311.79. Price is about fair value.

Above fair value, around its usual premium.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 131.37M. Growth 19.11%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 9.84% (beta 1.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 19.94M. Net debt 276.56M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare LGND

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-10-29—2.33—77.00M
2026-08-062.372.0163.69M61.30M
2026-05-141.631.8451.72M59.10M
2026-02-262.021.4659.67M55.59M
2025-11-063.091.97115.46M58.74M
2025-08-071.601.4247.63M43.87M
2025-05-081.331.2145.33M38.71M
2025-02-27-1.641.3742.81M39.03M
2024-11-07-0.391.3551.81M40.60M
2024-08-061.401.0641.53M33.04M
2024-05-071.200.7830.98M27.92M
2024-02-271.050.6628.10M25.64M
2023-11-081.020.6132.87M27.22M
2023-08-081.420.6426.37M24.74M
2023-05-042.280.8943.98M33.55M
2023-02-221.361.1950.38M44.09M
2022-11-070.410.4566.09M38.32M
2022-08-080.340.4357.42M37.73M
2022-05-040.580.6645.69M34.21M
2022-02-171.800.9772.47M65.09M
2021-11-091.581.0464.83M53.27M
2021-07-291.631.3684.67M70.49M
2021-05-031.411.1355.15M63.00M
2021-02-031.620.9969.99M62.99M
2020-10-301.040.9841.85M39.43M
2020-08-031.000.7641.42M31.48M
2020-05-060.890.6633.16M24.59M
2020-02-060.710.6427.00M24.34M
2019-11-050.490.6124.81M30.88M
2019-07-300.680.5524.99M20.21M
2019-05-021.161.0243.48M38.24M
2019-02-071.701.2259.59M42.76M
2018-11-081.321.0345.66M35.63M
2018-08-062.592.3490.04M81.35M
2018-05-081.551.2956.16M46.74M
2018-02-211.311.1950.46M45.84M
2017-11-090.690.6133.38M29.51M
2017-08-070.670.4628.00M19.22M
2017-05-090.570.6329.27M32.35M
2017-02-230.741.3038.19M36.36M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency Special.

Safety score 43/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. Dividend history is short. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
2010-07-02$0.462010-06-28—Special
2007-04-03$9.362007-04-052007-04-19Special

Insider trades

DateInsiderActionSharesPriceValue
2026-10-02Reardon AndrewBuy340$52.2717.77K
2026-10-02Reardon AndrewSell833$302.51251.99K
2026-10-02Reardon AndrewSell1.98K$303.54599.80K
2026-10-02Reardon AndrewSell1.53K$304.52467.43K
2026-10-02Reardon AndrewSell404$306.18123.70K
2026-10-02Reardon AndrewSell235$307.1972.19K
2026-10-02Reardon AndrewSell17$307.745.23K
2026-10-02Reardon AndrewSell340$52.2717.77K
2026-09-22Zimmermann MartineSell115$298.5034.33K
2026-09-10Zimmermann MartineSell1.20K$285.00342.00K
2026-09-03Reardon AndrewSell300$283.9985.20K
2026-09-03Reardon AndrewSell1.80K$285.17513.30K
2026-09-03Reardon AndrewSell2.12K$286.36605.65K
2026-09-03Reardon AndrewSell385$287.53110.70K
2026-09-03Reardon AndrewSell400$288.98115.59K
2026-08-12Espinoza OctavioBuy3.35K$68.74230.14K
2026-08-12Espinoza OctavioBuy7.17K$57.22410.32K
2026-08-12Espinoza OctavioBuy2.87K$55.75159.95K
2026-08-12Espinoza OctavioBuy2.07K$70.04145.26K
2026-08-12Espinoza OctavioBuy16.18K$52.84854.90K
2026-08-12Espinoza OctavioSell31.64K$292.069.24M
2026-08-12Espinoza OctavioSell2.87K$55.75159.95K
2026-08-12Espinoza OctavioSell7.17K$57.22410.32K
2026-08-12Espinoza OctavioSell16.18K$52.84854.90K
2026-08-12Espinoza OctavioSell3.35K$68.74230.14K
2026-08-12Espinoza OctavioSell2.07K$70.04145.26K
2026-08-12Haas JasonBuy6.14K$51.56316.48K
2026-08-12Haas JasonSell7.14K$292.812.09M
2026-08-12Haas JasonSell6.14K$51.56316.48K
2026-08-03Reardon AndrewBuy5.00K$52.27261.35K
2026-08-03Reardon AndrewSell105$284.1429.83K
2026-08-03Reardon AndrewSell33$284.559.39K
2026-08-03Reardon AndrewSell157$285.7444.86K
2026-08-03Reardon AndrewSell1.03K$286.80295.97K
2026-08-03Reardon AndrewSell1.21K$287.77349.36K
2026-08-03Reardon AndrewSell356$288.75102.79K
2026-08-03Reardon AndrewSell503$289.80145.77K
2026-08-03Reardon AndrewSell200$290.6058.12K
2026-08-03Reardon AndrewSell991$291.71289.09K
2026-08-03Reardon AndrewSell409$292.82119.76K
2026-08-03Reardon AndrewSell5.00K$52.27261.35K
2026-07-01Reardon AndrewBuy5.00K$52.27261.35K
2026-07-01Reardon AndrewSell396$308.99122.36K
2026-07-01Reardon AndrewSell104$310.2032.26K
2026-07-01Reardon AndrewSell1.12K$311.72348.81K
2026-07-01Reardon AndrewSell1.08K$312.28337.57K
2026-07-01Reardon AndrewSell700$313.46219.42K
2026-07-01Reardon AndrewSell100$314.5831.46K
2026-07-01Reardon AndrewSell900$315.78284.20K
2026-07-01Reardon AndrewSell600$317.15190.29K
2026-07-01Reardon AndrewSell5.00K$52.27261.35K
2026-06-30Reardon AndrewBuy132$160.7121.21K
2026-06-30Espinoza OctavioBuy17$160.712.73K
2026-06-30Davis Todd CBuy132$160.7121.21K
2026-06-16Sabba Stephen LBuy2.15K$66.13141.85K
2026-06-16Sabba Stephen LSell2.15K$254.00544.83K
2026-06-16Sabba Stephen LSell2.15K$66.13141.85K
2026-06-12Haas JasonBuy1.00K$51.5651.56K
2026-06-12Haas JasonBuy3.00K$51.56154.68K
2026-06-12Haas JasonSell3.00K$255.01765.03K
2026-06-12Haas JasonSell3.00K$51.56154.68K
2026-06-12Haas JasonSell1.00K$51.5651.56K
2026-06-12Haas JasonSell3.46K$256.08886.29K
2026-06-11Aryeh JasonSell4.50K$250.001.12M
2026-06-10Aryeh JasonSell500$250.00125.00K
2026-06-10LAMATTINA JOHN LSell257$247.2263.54K
2026-06-10LAMATTINA JOHN LSell232$248.1157.56K
2026-06-10LAMATTINA JOHN LSell697$249.53173.92K
2026-06-10LAMATTINA JOHN LSell3.40K$251.62856.75K
2026-06-05Aryeh JasonBuy836——
2026-06-05Aryeh JasonBuy2.94K$237.00696.31K
2026-06-05Zimmermann MartineBuy836——
2026-06-05Zimmermann MartineSell182$237.0043.13K
2026-06-05Zimmermann MartineBuy2.94K$237.00696.31K
2026-06-05Sabba Stephen LBuy836——
2026-06-05Sabba Stephen LBuy2.94K$237.00696.31K
2026-06-05LAMATTINA JOHN LBuy836——
2026-06-05LAMATTINA JOHN LBuy2.94K$237.00696.31K
2026-06-05KOZARICH JOHN WBuy836——
2026-06-05KOZARICH JOHN WBuy2.94K$237.00696.31K
2026-06-05Haas JasonBuy836——
2026-06-05Haas JasonBuy2.94K$237.00696.31K
2026-06-05Gray Nancy RyanBuy836——
2026-06-05Gray Nancy RyanBuy2.94K$237.00696.31K
2026-06-01Reardon AndrewBuy5.00K$52.27261.35K
2026-06-01Reardon AndrewSell491$223.95109.96K
2026-06-01Reardon AndrewSell677$225.20152.46K
2026-06-01Reardon AndrewSell1.43K$225.97323.59K
2026-06-01Reardon AndrewSell400$226.7890.71K
2026-06-01Reardon AndrewSell584$228.57133.49K
2026-06-01Reardon AndrewSell1.22K$229.47279.03K
2026-06-01Reardon AndrewSell200$230.4146.08K
2026-06-01Reardon AndrewSell5.00K$52.27261.35K
2026-05-27Espinoza OctavioBuy972$52.8451.36K
2026-05-27Espinoza OctavioBuy764$63.6248.61K
2026-05-27Espinoza OctavioSell764$63.6248.61K
2026-05-27Espinoza OctavioSell972$52.8451.36K
2026-05-13KOZARICH JOHN WBuy1.57K$69.51109.48K
2026-05-13KOZARICH JOHN WSell1.57K$223.50352.01K
2026-05-13KOZARICH JOHN WSell1.57K$69.51109.48K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 430, holders +62 vs prior quarter. Ownership 113.74%.

HolderSharesChangeChange %Value
BLACKROCK, INC.3.10M139.07K+4.70%980.19M
INVESCO LTD.1.20M378.04K+45.90%379.83M
VANGUARD PORTFOLIO MANAGEMENT LLC1.14M38.05K+3.46%359.81M
JUPITER TOPCO LLC1.04M1.04MNew328.91M
VANGUARD CAPITAL MANAGEMENT LLC870.95K22.86K+2.70%275.30M
STATE STREET CORP826.54K47.68K+6.12%261.25M
FMR LLC762.83K166.70K+27.96%241.12M
FRANKLIN TEMPLETON INC752.04K178.87K+31.21%237.71M
CONGRESS ASSET MANAGEMENT CO659.91K155.27K+30.77%208.59M
GEODE CAPITAL MANAGEMENT, LLC589.02K30.09K+5.38%186.21M
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.568.37K-4.94K-0.86%179.66M
CHICAGO CAPITAL, LLC553.43K-8.24K-1.47%174.94M
STEPHENS INVESTMENT MANAGEMENT GROUP LLC475.61K-19.06K-3.85%150.34M
DIMENSIONAL FUND ADVISORS LP429.31K4.08K+0.96%135.70M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/375.76K-35.78K-8.69%118.77M
GOLDMAN SACHS GROUP INC323.25K-57.87K-15.18%102.17M
LOOMIS SAYLES & CO L P291.81K-61.40K-17.38%92.24M
RICE HALL JAMES & ASSOCIATES, LLC270.05K-13.52K-4.77%85.36M
RANGER INVESTMENT MANAGEMENT, L.P.257.60K-10.35K-3.86%81.42M
NORTHERN TRUST CORP257.39K3.23K+1.27%81.36M
VICTORY CAPITAL MANAGEMENT INC253.76K-49.46K-16.31%80.21M
DEUTSCHE BANK AG\249.61K-56.50K-18.46%78.90M
NEUBERGER BERMAN GROUP LLC248.35K248.35KNew78.50M
GW&K INVESTMENT MANAGEMENT, LLC246.88K97.38K+65.14%78.04M
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC210.43K-2.46K-1.16%66.51M

Earnings and financials

Ligand Pharmaceuticals Incorporated (LGND) trades at $311.79, with a market cap of $6.22B and a trailing P/E of 30.80. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
108973000141102000251453000120282000163562000241544000196245000131314000167133000268087000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Ligand Pharmaceuticals (LGND) Financials: Revenue & Earnings

LGND$311.79+0.06 +0.02%

$6.22B

Market Cap

30.80

P/E

33.36

Forward P/E

58

Score

Price History